ABSI ABSCI CORP

Absci to Participate in Upcoming Investor Conferences

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.

  • H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

    Fireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time
  • 24th Annual Needham Virtual Healthcare Conference

    Fireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time

Interested parties may access live and archived webcasts of the fireside chat sessions on the company’s investor relations website at: .

About Absci

is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our ™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit  and follow us on LinkedIn (), X (Twitter) (), and .

Investor Contact

Alex Khan

VP, Finance & Investor Relations

Media Contact



EN
26/03/2025

Underlying

ABSIABSCI CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ABSCI CORP

 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD

Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs AUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLOBE NEWSWIRE) -- , a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with and to accelerate generative AI-driven drug discovery. Absci’s generative AI Drug Creation Platform leverages OCI’s AI infrastructure and AMD’s latest hardware, enabling it to consolida...

September 11, 2025 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci Expands ABS-201 Scientific Advisory Board with Addition of Leadi...

Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia. VANCOUVER, Wash. and NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced that world-renowned dermatologists Dr. Rodney Sinclair and Dr. David Goldberg have joined its ABS-201 Scien...

August 25, 2025 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci to Participate in Upcoming Investor Conferences

Absci to Participate in Upcoming Investor Conferences VANCOUVER, Wash. and NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the following upcoming investor conferences: 2025 Wells Fargo Healthcare Conference (Boston, MA) Hosting 1x1 meetings on Wednesday, September 3 Morgan Stanley 23rd Annual Global Healthcare Conference (New York, NY) Fireside chat on Monday, September 8 at 3:20 p.m. Eastern Time ...

August 20, 2025 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci Reports Business Updates and Second Quarter 2025 Financial and O...

Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028 Expanded ongoing collaboration with Almirall, with election of a second target focused on dermatological indications VANCOUVER, Wash. and NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with ...

August 12, 2025 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Almirall and Absci Expand AI Drug Creation Collaboration Adding a Seco...

Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target Almirall selects second target in AI Drug Creation collaborationExpanded collaboration builds on Absci’s successful de novo molecule design for difficult‑to‑drug targets in the first stage of the collaboration with Almirall BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch